Navigation Links
ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health
Date:6/24/2009

The Blanket Purchase Agreement will expedite the purchasing process for groups within the National Institutes of Health.

IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today that the National Institutes of Health established a Blanket Purchase Agreement (BPA) with the Company. The Agreement covers all products and services offered by ChromaDex. This includes botanical reference materials, phytochemicals, bulk chemical production, analytical testing services, analytical method development, contract research, isolation of compounds, chemical synthesis and natural product libraries.

The BPA makes it easier for the various Institutes within NIH to do business with ChromaDex.

"We are honored to be recognized by the National Institutes of Health with the issuance of a Blanket Purchase Agreement to ChromaDex," said Frank Jaksch, co-founder and CEO of ChromaDex. "There is considerable work taking place at NIH in the areas of natural products, dietary supplements and alternative medicines. As a leader in this field, ChromaDex will be working closely with NIH to provide products and services to support their efforts."

About National Institutes of Health

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability. Composed of 27 Institutes and Centers, the NIH provides leadership and financial support to researchers in every state and throughout the world. For over a century, the National Institutes of Health has played an important role in improving the health of the nation.

About ChromaDex

ChromaDex is a world leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


'/>"/>
SOURCE ChromaDex Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ChromaDex Reports 2009 Q1 Financial Results
2. ChromaDex Awarded Nutrition Business Journal Scientific Achievement
3. ChromaDex Partners With Cargill to Provide Global Quality Control Methods and Standards for Sweet Components of Stevia
4. ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds
5. Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
6. Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age
7. DFG establishes nine new collaborative research centers
8. IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France
9. Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China
10. Study in Nature Medicine establishes major new treatment target in diseased arteries
11. New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: